Alluvi, known as BI 4744, presents a promising advance in weight loss treatment. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates remarkable results in https://alluvihealthcare684179.plpwiki.com/user